Ankle injury management (AIM) : design of a pragmatic multi-centre equivalence randomised controlled trial comparing close contact casting (CCC) to open surgical reduction and internal fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years by Willett, Keith et al.
 http://wrap.warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
Original citation: 
Willett, Keith, Keene, David J., Morgan, Lesley, Gray, Bridget, Handley, Robert, 
Chesser, Tim, Pallister, Ian, Tutton, Elizabeth, Knox, Christopher R., Lall, Ranjit, Briggs, 
Andrew and Lamb, S. E. (Sallie E.). (2014) Ankle injury management (AIM) : design of a 
pragmatic multi-centre equivalence randomised controlled trial comparing close contact 
casting (CCC) to open surgical reduction and internal fixation (ORIF) in the treatment of 
unstable ankle fractures in patients over 60 years. BMC Musculoskeletal Disorders, 
Volume 15 (Number 1). Article number 79. 
Permanent WRAP url: 
http://wrap.warwick.ac.uk/64339         
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 2.0 Generic (CC 
BY 2.0) license and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/2.0/ 
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may 
be cited as it appears here. 
 
For more information, please contact the WRAP Team at: publications@warwick.ac.uk  
Willett et al. BMC Musculoskeletal Disorders 2014, 15:79
http://www.biomedcentral.com/1471-2474/15/79STUDY PROTOCOL Open AccessAnkle Injury Management (AIM): design of a
pragmatic multi-centre equivalence randomised
controlled trial comparing Close Contact Casting
(CCC) to Open surgical Reduction and Internal
Fixation (ORIF) in the treatment of unstable ankle
fractures in patients over 60 years
Keith Willett1*, David J Keene1, Lesley Morgan1, Bridget Gray1, Robert Handley2, Tim Chesser3, Ian Pallister4,
Elizabeth Tutton1, Christopher Knox5, Ranjit Lall5, Andrew Briggs6 and Sarah E Lamb1,5Abstract
Background: Ankle fractures account for 9% of all fractures with a quarter of these occurring in adults over
60 years. The short term disability and long-term consequences of this injury can be considerable. Current opinion
favours open reduction and internal fixation (ORIF) over non-operative treatment (fracture manipulation and the
application of a standard moulded cast) for older people. Both techniques are associated with complications but
the limited published research indicates higher complication rates of fracture malunion (poor position at healing)
with casting. The aim of this study is to compare ORIF with a modification of existing casting techniques, Close
Contact Casting (CCC). We propose that CCC may offer an equivalent functional outcome to ORIF and avoid the
risks associated with surgery.
Methods/Design: This study is a pragmatic multi-centre equivalence randomised controlled trial. 620 participants
will be randomised to receive ORIF or CCC after sustaining an isolated displaced unstable ankle fracture. Participants
will be recruited from a minimum of 20 National Health Service (NHS) acute hospitals throughout England and
Wales. Participants will be aged over 60 years and be ambulatory prior to injury. Follow-up will be at six weeks and
six months after randomisation. The primary outcome is the Olerud & Molander Ankle Score, a functional patient
reported outcome measure, at 6 months. Follow-up will also include assessments of mobility, ankle range of
movement, health related quality of life and complications. The six-month follow-up will be conducted face-to-face
by an assessor blinded to the allocated intervention. A parallel economic evaluation will consider both a health
service and a broader societal perspective including the individual and their family. In order to explore patient
experience of their treatment and recovery, a purposive sample of 40 patients will also be interviewed using a
semi-structured interview schedule between 6-10 weeks post treatment.
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Discussion: This multicentre study was open to recruitment July 2010 and recruitment is due to be completed in
December 2013.
Trial registration: Current Controlled Trials ISRCTN04180738.
Keywords: Ankle, Fracture, Trauma, Orthopaedics, Cast, Surgery, Conservative, Operative, AdultBackground
In 2009/10 Hospital Episode Statistics for the National
Health Service (NHS) in the United Kingdom recorded
343,536 fractures that required admission or surgery.
Ankle fractures account for 9% of all fractures [1] and
have an increasing incidence in the population aged over
50 years, with the trend set to continue [2,3]. A Scottish
study reported an incidence of 132 fractures per 100,000
in men, and 112 fractures per 100,000 in women, per
year, with the highest incidence of 248 per 100,000 per
year occurring in women between the ages of 75 and 84
[3]. A three-fold increase is predicted from 2000 to 2030
as the population ages [4]. Ankle fractures have a sub-
stantial and lasting impact on mobility and related func-
tions (e.g. standing, walking and stair climbing), with
older adults often having the worse outcomes [5-9]. This
can affect the ability to live independently.
For the young adult patient the established treatment is
open reduction and internal fixation (ORIF), in which the
bone fragments are repositioned at surgery and held in
place until healing (union) by plates and/or screws. The in-
cidence of wound problems in patients under 60 years of
age undergoing surgery is also low (typically 1-5% of cases).
It is more difficult to achieve successful surgical outcome in
older people (adults aged over 60 years), because of a higher
prevalence of co-morbidities resulting in lower bone dens-
ity, frail skin and impaired wound healing. Poor bone qual-
ity (resulting from osteoporosis) directly affects the efficacy
of stabilisation treatment methods for the bone fracture
fragments [10]. Such fractures, because of the greater frag-
mentation and poor bone strength, tend to be less stable
after repositioning and the holding strength of fixation
screws can be diminished up to 10 fold [11]. This can ren-
der fixations incompetent and prevent early joint move-
ment and weight-bearing – the accepted advantages of the
surgical fixation approach in the younger patient. Other
common co-morbidities in the older patient (peripheral
vascular disease, chronic venous insufficiency, late onset
diabetes, and/or oedema from heart failure) directly affect
the lower limb skin and soft tissue tolerance of surgical
wounds or traditional casts.
In older people, rates of postoperative complications from
ankle fracture fixation surgery are high, for example 33% of
patients required reoperation for removal of implants in
one study [12]. Soft tissue complications after surgery also
have a negative effect on long-term functional outcome[13]. Other case series support ORIF for a more predictable
good outcome and acceptably low complication rates
[14,15]. Despite the common occurrence of ankle fractures
in older people published research is considered low quality
[16]. Non-consecutive case series, non-randomised and
retrospective studies dominate. Follow up is often incom-
plete, and there is a reliance on data extracted from records
and radiographs as opposed to the patient-important and
functional outcomes. A 2012 Cochrane review [17], com-
paring surgical versus non-operative treatment for ankle
fractures, included 292 participants in three randomised
controlled trials [18-20] and one quasi-randomised con-
trolled trial [21]. The authors concluded that there is cur-
rently insufficient evidence of the effects of surgical versus
conservative treatment on outcome after ankle fracture and
confirmed the need for an adequately powered clinical trial.
Currently ORIF is more commonly used than non-
operative treatment for ankle fracture in older people. Both
are associated with complications but the limited published re-
search indicates higher rates of loss of fracture reduction or
malunion (poor position at healing) with traditional casting
[17]. Traditional casting methods (an external support formed
by an under layer of stockinette, layers of wool roll and felt,
and a rigid outer layer made of plaster of Paris and/or syn-
thetic material) can also create pressure sores. Many surgeons
make a clinical judgement alone on a) the likely tolerance of a
patient’s skin for surgical incisions and b) the bone quality and
chance of achieving implant fixation. For patients judged as
higher risk for open surgery, some surgeons may select
manipulation and traditional casting, assuming fewer
complications but with a higher risk of malunion.
A modification of the traditional casting treatment, with
the potential of improved fracture stabilisation and lower
skin damage risk, has now been identified – Close Contact
Casting (CCC). This is a modification of “total contact
casting” used extensively and successfully for more than
20 years in treating leg ulcers in diabetics who have frail
skin [22-24]. CCC works by creating an intimate, ana-
tomic, very close fit to the lower leg shape so dissipating
forces evenly over all the skin, avoiding high local contact
areas, protecting and promoting skin recovery.
A feasibility study has confirmed the viability of the study
design and outcome measures proposed. It has also provided
data to inform the estimates of sample size, along with re-
cruitment rates. A parallel vascular laboratory investigation
has confirmed the potential for improved skin viability
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properly constructed randomised controlled trial compar-
ing CCC to ORIF, both for patient-important outcomes
and cost effectiveness. This research question was a prod-
uct of a research priority setting exercise undertaken with
the orthopaedic trauma surgeon members of the UK As-
sociation for Osteosynthesis (AOUK) to identify research
areas of importance for surgical fracture treatment [26].
Primary objective
To determine if the application of the Close Contact Cast-
ing technique (CCC) for displaced ankle fractures in older
adults results in an equivalent outcome compared to the
standard care of open surgical reduction and internal fix-
ation (ORIF) in terms of function, complications, quality
of life and patient satisfaction with treatment.
Secondary objectives
An economic evaluation will run in parallel to the study
and will consider the costs of the two treatments to (i) the
NHS, and (ii) the broader societal perspective including to
the individual and their family. Potential complications,
readmissions, revision surgery rates and mortality will
be monitored carefully and considered in the overall
appraisal of clinical and cost effectiveness.
Methods/Design
Summary of study design
A pragmatic multi-centre randomised controlled equiva-
lence trial with parallel prospective economic evaluation.
Participants will be randomised to receive ORIF or CCC
after admission for surgery for displaced unstable ankle
fractures in the Trauma and Orthopaedic Surgery de-
partments of a minimum of 20 NHS acute hospitals.
Study participants
Men or women aged over 60 years with displaced unstable
fracture of the ankle who meet the eligibility criteria:
Inclusion criteria
 Men or women aged over 60 years
 Isolated displaced unstable ankle fracture
 Ambulatory prior to the injury - in any capacity
 Capable of giving informed consent
 Capable of adhering to post-operative instructions
 Resident within the catchment area of a recruiting
hospital
 Can attend for 6-month follow up
Exclusion criteria
 Established critical limb ischaemia
 Insulin dependent diabetes mellitus Active leg ulceration
 Open fractures
 Serious concomitant disease - metastatic disease or
terminal illness
 Clinically substantial degenerative or inflammatory
arthritis (in the ankle)
 Unfit for general anaesthetic
 Cognitive impairment - Mini-Mental State Exam
(MMSE) of under 16/30 [27]
 Patient unwilling to give informed consent.Participant approach and recruitment
The treating surgical team will undertake the initial
approach to participants. It will be important at this
stage that clinicians do not inadvertently influence poten-
tial participants by describing or emphasising only one of
the possible treatment options. If the participant is willing,
a member of the research team will explain the study in
more detail and check eligibility criteria. A Mini-Mental
State Examination (MMSE) to assess cognitive function
will be undertaken prior to randomisation (see eligibility
criteria). Potential participants will be given as long a
time as possible to consider participation; traditionally
treatment is delayed a few days to allow injury swell-
ing to settle.Interventions
The surgical techniques, designated by the study, are
common in UK surgical practice and lie within the
expertise of UK trained orthopaedic surgeons. Train-
ing on Close Contact Casting (CCC) will be provided
for surgeons by a member of the trial team. All cases
will conform to the NHS standard of being performed
under consultant supervision. Both study interventions
are applied in theatre under general or regional anaes-
thesia. We will record time to treatment and type of an-
aesthesia (regional, general or both). Surgeons will be
advised that talar tilt or shift resulting in significant
joint incongruence would be considered unacceptable
but as a pragmatic trial this will ultimately be a local
clinical decision. Prior to definitive intervention, pa-
tients typically have their ankle immobilised in a type
of temporary cast (or less frequently with an external
fixator).Standard care
Open surgical reduction and internal fixation (ORIF)
Surgeons will be permitted to choose from the range of
implants that are used in the UK, and will comply with
internationally recognised AO principles of Fracture
Management [28].
Willett et al. BMC Musculoskeletal Disorders 2014, 15:79 Page 4 of 9
http://www.biomedcentral.com/1471-2474/15/79Intervention
Manipulation under anaesthetic in theatre and application
of Close Contact Cast (CCC)
Standardisation of the casting materials, cast design and
application, and moulding technique will be achieved by
surgeon instruction (training session and access to train-
ing videos and documentation). The method of closed
fracture manipulative reduction of deformity will be at
the discretion of individual surgeons and this falls within
the common contemporary skills set of senior surgical
trainees and consultants. The CCC is applied once major
swelling has subsided at a similar time to that when
open surgery would be considered. The use of specific
moulding points and sited pressure pads prevents fracture
displacement whilst minimising the risk of skin damage.
In the weeks following the initial cast application, and
after any re-applications of the cast (if required), partici-
pants in the CCC group will require monitoring X-rays to
check maintenance of fracture position.
It is possible that in some cases, after randomisation,
the intervention delivered will necessarily be changed.
We anticipate the following:
 After randomisation at the point of intervention with
anaesthesia commenced, the temporary cast is
removed. The ankle skin condition may have
deteriorated such that the surgeon considers one or all
necessary surgical incisions to be unsafe. If randomised
to ORIF, an alternative treatment* would be given.
 After randomisation at the point of intervention with
anaesthesia commenced, a fracture may prove
irreducible by closed manipulation. The surgeon would
necessarily proceed to open surgical reduction. If that
is required, internal fixation would be undertaken.
 If there is an unacceptable loss of position by either
treatment method prior to fracture healing, the
surgeon will adopt the treatment approach* best
judged to achieve a favourable outcome.
 Very rarely a combination of bone and skin fragility
and gross joint instability will exclude either
intervention. The surgeon will apply a temporising
external fixator and definitive treatment* will be at
the surgeon’s discretion.
* alternative treatments include: i) traditional plaster
cast, ii) external fixation iii) ORIF. CCC will be excluded
as an option outside the group randomised to CCC.
Standardisation of other treatments
Each hospital will follow its own antibiotic prophylaxis
protocol for the type of implant insertion procedure for
the ORIF group. No antibiotics will be routinely admin-
istered to the CCC patients in theatre. Thromboprophy-
laxis will reflect local hospital policy. In line with normalpractice, the expectation is the majority of participants
will not begin partial or full weight-bearing until at least
4 weeks after intervention [17,29]. However, the post-
operative management plan, including the progression of
weight-bearing, will be at the discretion of the individual
surgeon. Rehabilitation will focus on early restoration of
independent mobility, in as timely a fashion as possible.
All participants will be reviewed by an orthopaedic sur-
geon independent to the study team to deal with any on-
going symptoms such as pain. It will not be possible to
blind the treating surgeon or radiograph assessors. The
implants, or their absence, will be apparent on the radio-
graphs as will the soft tissue scars on examination.Learning and expertise effects
This is a pragmatic study. We will monitor and analyse
data to establish the extent, if any, of learning or expertise
effects. It is common practice that surgeons have particu-
lar expertise in selected techniques, and for surgical teams
to organise their workloads so that expertise is utilised to
best effect. This study will not interfere with this dynamic.
It is therefore not easy to anticipate the direction of ex-
pertise and learning effects. For each surgeon participating
in the study, we will collect the following information: his-
torical experience and preferences for ORIF and casting,
grade of surgeon, time since first operation on the study
and, if applicable, years since obtaining a certificate of
completion of specialist training. These data will be sum-
marised by recruitment centre and by treatment group
and appropriate summary statistics will be produced in-
cluding tests of association between surgeon experience
and the procedures carried out. This will then guide rec-
ommendations on implementation and training if the
technology proves effective.Baseline assessments
Baseline assessments will be undertaken by one of the
research team following consent and prior to randomisa-
tion. None of the participants will be ambulatory at the
baseline phase, but we will collect information about
pre-injury mobility status using a retrospective report
from the Olerud & Molander ankle score [30] as well as
health related quality of life using the EQ-5D [31] and
SF-12 [32]. Although not ideal, recall is the only method
that we will have of assessing pre-fracture abilities. As
the recall period is relatively short, typically a couple of
days (up to two weeks), we do not anticipate problems.
The type of residence in the month prior to admission
will be recorded, as will the level of support provided
and whether the participants lived alone prior to the in-
jury. Information on pre-injury mobility status, medical
history, smoking, alcohol intake, allergies, medication
and care requirements will be collected.
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Participants will be asked to attend study assessments at six
weeks and six months. The outcomes and time points for
the study are outlined in Table 1. The primary outcome
measure is the Olerud & Molander Ankle Score, a func-
tional outcome questionnaire [30]. The Olerud & Molander
ankle score is a rating scale from 0 (totally impaired) to
100 (completely unimpaired) based on 9 items. The re-
sponse to each of the 9 items is assigned a score and the
summation of these scores makes up the overall score.
Mobility, assessed using the Timed ‘Get up and Go’ test
[33], has been included as an outcome at 6 months. The
Timed ‘Get up and Go’ test is a test specifically designed
for frail older people, it records time taken to get up from
a chair, walk a short distance, turn, and sit down again.
Performance tests are a recognised standard for measuring
mobility and associations with important end points in-
cluding risk of falling, functional decline and institutionali-
sation [34]. We will report and analyse the pain sub-scales
of the Olerud & Molander Score and the EQ-5D separ-
ately. Health related quality of life will be assessed using
the EQ-5D and SF-12. We will also note the date partici-
pants commence partial weight-bearing.
Cost-effectiveness will be measured by an economic
analysis conducted alongside the study. The outcomes
will incorporate the elements of duration of inpatient
hospital stay, theatre time/implant costs, fracture clinic
visits, additional treatment costs and social dependency/
support change.
At six months a health professional, who is blind to
treatment assignment, will complete the clinical measure-
ments and ensure completion of the study questionnaires.Table 1 Outcome measures by time-point for the AIM study
Outcome
Olerud & Molander ankle score
EQ-5D +
SF-12
General health - medical history, smoking, alcohol intake, allergies
and medication
Social circumstances - place of residence, mobility status and care
requirements
Ankle range of movement - goniometer measurement of dorsiflexion,
plantarflexion, inversion and eversion, uninjured and injured ankles.
Radiological measurements of fracture and ankle joint congruence
Theatre procedure data - Time in and out of theatre, experience of
operating surgeon, implants used, type of anaesthetic, complications
Patient satisfaction measure - 2 questions (Likert-type scale)
Health economics questionnaire
Timed ‘Get up and Go’ test
+ indicates measure recorded.We are confident that with safeguards it will be pos-
sible to blind the assessors to assignment. Presence or
not of the surgical incision will be obscured by an
opaque bandage applied by a research nurse/therapist
prior to the participant meeting the blinded assessor.
Patients unable to attend will be contacted by tele-
phone, or visited at home. We will undertake an analysis
of the success of the blinding strategy using outcomes
from questions asking blinded assessors to indicate if
they believe they know the intervention allocated and/or
received.
Radiological outcomes, complications and further surgery
For both groups radiographs will be taken post-
operatively, at six weeks and six months. Fracture union
and joint position will be assessed on standard antero-
posterior (ankle mortise view) and lateral radiographs
using standard measures of joint congruence, fracture
angulation, fibular shortening and subluxation [35]. The
radiographs will be reviewed centrally by a trained inde-
pendent assessor. Measurements will then be verified by
two independent surgeons. Any disagreement will be re-
solved by a radiologist.
Adverse events resulting from medical co-morbidities
or anaesthesia (part of normal care) will only be re-
corded as adverse events and not reported as serious ad-
verse events. Expected complications including wound
breakdown, loss of fracture position, etc. will also be re-
corded as adverse events only. Other fractures sustained,
further surgery or major illness resulting in disability in
the study period will also be recorded. A serious adverse
event will be any untoward medical occurrence that:Baseline assessments Theatre 6 weeks 6 months
(Outcome assessor
blinded)
+ (prior to injury status) + +
(day before injury status and
on the day of assessment)
+ +
+ (prior to injury status) + +
+
+
+ +
+ + +
+
+ +
+ +
+
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 Results in death related directly to the surgical
intervention at any time
 Life or limb threatening complication
 Re-hospitalisation (except a hospital stay for removal
of syndesmosis screws which will be reported as an
adverse event).
We plan to contact participants for extended follow
up at least two years after intervention but this phase
will be a separate sub-study.
Randomisation
Randomisation will take place following screening and
baseline assessments and the unit of randomisation will
be the individual. We will use a remote 24-hour tele-
phone randomisation service, computer generation of
the allocation code once the participant is registered, en-
sures allocation concealment. Randomisation will be
stratified by centre and fracture pattern, using infra/
trans-syndesmotic (Weber A/B) and supra-syndesmotic
categories (Weber C).
Sample size
Given the paucity of data in the published literature the
feasibility pilot data have been used as a primary source
to inform estimates of variance and treatment effects
measured using the Olerud & Molander score, and a
range of secondary outcomes. We have tested the sensi-
tivity of these estimates against data available in the pub-
lished literature.
Although the original sample size estimate was based
on a difference in proportions this was modified by the
DMEC as data from the pilot study confirmed data to be
normally distributed and that analysis based on a con-
tinuous score would be more efficient and meaningful.
Parameters for the sample size were informed by data
from the pilot study, known only to the study statisti-
cians and DMEC. We utilised one-sided testing (p =
0.05) since we are not trying to prove that the new treat-
ment is better than the standard, and gain considerable
statistical efficiency [36]. Power was be set at 80% ac-
cording to Food and Drug Administration (FDA) recom-
mendations for bioequivalence studies [37].
Based on the mean difference observed between the
groups of 2.6 points in the first 71 participants from the
pilot study, pooled standard deviation of 16.2, an equiva-
lence margin of +/- 6 points on the Olerud & Molander
Ankle Score, yields a final sample size of 560 in total
[36]. We inflated for loss to follow up of near 10% yield-
ing a total sample size of 620. Published estimates to in-
form the selection of equivalence margins using the
Olerud & Molander Score was non-existent. Using the
pilot data to calculate standardised effects sizes, theequivalence margin includes small differences (<0.37)
but excludes moderate or large treatment differences.
This was consistent with clinical opinion supporting a 6
point margin excluding clinically important differences
in this condition gathered in an informal survey of
orthopaedic surgeons, and published data on the minim-
ally clinically important differences for similar scores (Foot
and Ankle Score, and visual analogue pain scores in acute
injury) that report minimally clinically important differ-
ences greater than 10 points on a 100 point scale.
Analysis of endpoints
In equivalence testing a maximum clinical difference
(ΔT) is pre-specified at a level within which the two
treatments can be considered not to differ in any clinic-
ally meaningful way. Therefore, the relevant null hypoth-
esis is that a difference of greater than ΔT exists in
either direction, H0: Δ ≤ -ΔT or Δ ≥ΔT, and the trial is
targeted at disproving this in favour of the alternative
that no clinical difference exists, HA: -ΔT <Δ <ΔT. FDA
regulations recommend both a treatment received (per-
protocol) and intention to treat analysis, aiming to dem-
onstrate equivalence [37]. Use of an ITT approach as in
a superiority trial sometimes increases the chance of
falsely claiming equivalence [38,39]. Initially, a per-
protocol analysis will be undertaken where only the pa-
tients who received their allocated treatment will be ana-
lysed and those patients who did not, will be excluded
from the analysis. Following this an intention to treat
analysis will be carried out where all randomised pa-
tients will be analysed according to the treatment they
were randomised to.
The result of the analysis of the primary endpoint
should be one of the following:
 The confidence interval for the difference between
the two treatments lies entirely within the
equivalence range, -ΔT to ΔT, so that equivalence
may be concluded with only a small probability of
error.
 The confidence interval covers at least some points
that lie outside the equivalence range, so that
differences of potential clinical importance remain a
real possibility and equivalence cannot safely be
concluded.
 The confidence interval is wholly outside the
equivalence range (though this is likely to be rare).
As well as assessing if equivalence is demonstrated in
either case this will also form part of an additional sensi-
tivity analysis to assess the range of potential biases that
could have resulted from loss to follow-up, protocol de-
viations, withdrawal (and mortality). Numerical and
graphical summaries of all the data will be compiled,
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mates of treatment effect will be reported with 95% confi-
dence intervals and a figure showing confidence intervals
and margins of equivalence will also be presented. Our
main analytical methods will be generalised linear models,
and all analyses will adjust for important baseline co-
variants to maximise precision.
The Olerud & Molander Ankle Score at 6 months is the
primary outcome in this study and will be compared be-
tween treatment groups as the dependent variable in a
linear regression model for the primary analysis. The treat-
ment difference will be based on the estimates of the ad-
justed means and 95% confidence intervals. The Olerud &
Molander Ankle score will also be presented as an ordinal
outcome in a secondary analysis using ordered logistic re-
gression or non-proportional odds models, depending on
the validity of the proportional odds assumption, will be
carried out. Secondary outcome measures will be similarly
analysed with logistic regression models being used for cat-
egorical data and linear regression models for continuous
data. Time to event data (e.g. time to discharge) will be
analysed using a log-rank test. Any patients who have not
experienced an event at the time point of interest or with-
drew will be censored. The proportion in each treatment
group experiencing an event over time will be illustrated
using a Kaplan-Meier curve. The p-value and a hazard ra-
tio with its 95% CI from a Cox proportional hazards model
will also be presented. The proportional hazards assump-
tion across treatment arms will be checked graphically
using a log-cumulative hazard plot. A data analysis plan
will be agreed with the Independent Data Monitoring
Committee.
Economic analyses
The costs of the treatment will include implants, cast ma-
terial, radiographs, surgical operating time, duration of
hospital admission, rehabilitation, and post-operative care.
Resource use will be collected during the follow up period
and will consider major costs falling on the health service
and personal social services (corresponding to the NICE
reference case). We will also look at the broader societal
perspective to include social services costs and costs fall-
ing on individual patients/carers. These will be valued in
monetary terms by applying unit costs from standard
sources such as the NHS Reference costs and the PSSRU
Costs of Health and Social Care. The outcome measure
will be the Quality Adjusted Life Year (QALY), based on
the EQ-5D instrument with utility weights taken from the
UK General Population tariff [40]. All costs and outcomes
will be discounted at 3.5% per annum as per the NICE ref-
erence case [41].
Two timeframes will be considered for the economic
evaluation - a six-month timeframe to correspond to the
observed data from the clinical trial and a lifetime analysiswhich will be based on projection of the clinical trial data
using decision-analytic modelling techniques [42].
Uncertainty for the six-month analysis corresponding to
the period of the trial will be handled through non-
parametric bootstrapping. Uncertainty for the additional
parameters introduced as part of the modelling projection
will be handled using probabilistic sensitivity analysis
based on Monte Carlo simulation. Sensitivity of the ana-
lysis to individual parameter uncertainty as well as overall
decision uncertainty will be assessed and presented [43].
A separate sensitivity analysis will explore the potential
importance of including productivity (indirect) costs of
patients/carers alongside direct costs in the societal per-
spective analysis. This analysis will be based on estimates
of days lost from work in combination with alternative
methods for valuing a day’s productivity.
Qualitative study
In order to explore patient experience of their treatment
and recovery, a purposive sample of 40 patients will be
interviewed using a semi-structured interview schedule
between six to ten weeks post-treatment. The sample
will cover patients from: both treatment options; two
study sites; a range of age, gender and accommodation.
Participants will be fully informed and provide written
consent. The interview will be conversational in style to
allow patients to identify their experiences and the issues
that concern them. The research question will be; what
are the experiences of patients with an unstable ankle
fracture? The key interview questions will cover what it
is like to have an unstable ankle fracture; their experi-
ences of treatment, what it is like living with a cast and
their experience of treatment with surgery. This will be
followed by prompts such as: tell me more about that;
how did that affect you; how did you feel about that;
how did you manage. To ascertain the impact of the trial
on the participants they will also be asked, what is it like
to take part in a trial. The interview will be taped and
transcribed verbatim. Analysis will be line by line, identi-
fying codes, building categories and themes, drawing on
the work of Miles and Huberman [44]. NVivo7, a soft-
ware package for qualitative data, will be used to help
with data management. The intention is to understand
how patients make sense of their treatment and recovery
and whether there are any differences in experience be-
tween the two treatments.
Ethics
The Oxfordshire Research Ethics Committee has given
approval for this study. We will comply with the Medical
Research Council Good Clinical Practice guidelines [45],
and the trial will run under the Standard Operating Pro-
cedures of Warwick University Clinical Trials Unit and
Oxford University. An independent data monitoring
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http://www.biomedcentral.com/1471-2474/15/79committee will meet twice yearly, with an option to in-
crease if specific concerns arise.
Reporting
The trial will be reported in accordance with the
CONSORT statement [46] and its extensions relating to
non-pharmologic [47], pragmatic [48] and equivalence
trials [39].
Discussion
This multicentre study was open to recruitment July
2010 and is due to be completed in December 2013.
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